Advertisement

Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Prescribing in Patients With Diabetes Mellitus With and Without Cardiovascular Disease

Published:November 21, 2022DOI:https://doi.org/10.1016/j.amjcard.2022.10.041
      Sodium-glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP1-RAs) reduce cardiovascular events and mortality in patients with type 2 diabetes mellitus (T2DM). We sought to describe trends in prescribing for SGLT2is and GLP1-RAs in diverse care settings, including (1) the outpatient clinics of a midwestern integrated health system and (2) small- and medium-sized community-based primary care practices and health centers in 3 midwestern states. We included adults with T2DM and ≥1 outpatient clinic visit. The outcomes of interest were annual active prescription rates for SGLT2is and GLP1-RAs (separately). In the integrated health system, 22,672 patients met the case definition of T2DM. From 2013 to 2019, the overall prescription rate for SGLT2is increased from 1% to 15% (absolute difference [AD] 14%, 95% confidence interval [CI] 13% to 15%, p <0.01). The GLP1-RA prescription rate was stable at 10% (AD 0%, 95% CI −1% to 1%, p = 0.9). In community-based primary care practices, 43,340 patients met the case definition of T2DM. From 2013 to 2017, the SGLT2i prescription rate increased from 3% to 7% (AD 4%, 95% CI 3% to 6%, p <0.01), whereas the GLP1-RA prescription rate was stable at 2% to 3% (AD 1%, 95% CI −1 to 1%, p = 0.40). In a fully adjusted regression model, non-Hispanic Black patients had lower odds of SGLT2i or GLP1-RA prescription (odds ratio 0.56, 95% CI 0.34 to 0.89, p = 0.016). In conclusion, the increase in prescription rates was greater for SGLT2is than for GLP1-RAs in patients with T2DM in a large integrated medical center and community primary care practices. Overall, prescription rates for eligible patients were low, and racial disparities were observed.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Centers for Disease Control and Prevention. National Diabetes Statistics Report 2020. Available at: https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf. Accessed on XXX.

        • Das SR
        • Everett BM
        • Birtcher KK
        • Brown JM
        • Cefalu WT
        • Januzzi Jr, JL
        • Kalyani RR
        • Kosiborod M
        • Magwire ML
        • Morris PB
        • Sperling LS
        2018 ACC Expert Consensus Decision Pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the American College of Cardiology Task Force on Expert consensus Decision Pathways.
        J Am Coll Cardiol. 2018; 72: 3200-3223
        • Gregg EW
        • Hora I
        • Benoit SR.
        Resurgence in diabetes-related complications.
        JAMA. 2019; 321: 1867-1868
        • Rawshani A
        • Rawshani A
        • Franzén S
        • Eliasson B
        • Svensson AM
        • Miftaraj M
        • McGuire DK
        • Sattar N
        • Rosengren A
        • Gudbjörnsdottir S.
        Mortality and cardiovascular disease in type 1 and type 2 diabetes.
        N Engl J Med. 2017; 376: 1407-1418
      2. Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes.
        JAMA. 2019; 321: 1720-1721
        • Zelniker TA
        • Wiviott SD
        • Raz I
        • Im K
        • Goodrich EL
        • Bonaca MP
        • Mosenzon O
        • Kato ET
        • Cahn A
        • Furtado RHM
        • Bhatt DL
        • Leiter LA
        • McGuire DK
        • Wilding JPH
        • Sabatine MS.
        SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
        Lancet. 2019; 393: 31-39
        • Sattar N
        • Lee MMY
        • Kristensen SL
        • Branch KRH
        • Del Prato S
        • Khurmi NS
        • Lam CSP
        • Lopes RD
        • McMurray JJV
        • Pratley RE
        • Rosenstock J
        • Gerstein HC.
        Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials.
        Lancet Diabetes Endocrinol. 2021; 9: 653-662
        • Marso SP
        • Daniels GH
        • Brown-Frandsen K
        • Kristensen P
        • Mann JFE
        • Nauck MA
        • Nissen SE
        • Pocock S
        • Poulter NR
        • Ravn LS
        • Steinberg WM
        • Stockner M
        • Zinman B
        • Bergenstal RM
        • Buse JB
        LEADER Steering Committee, LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes.
        N Engl J Med. 2016; 375: 311-322
        • Neal B
        • Perkovic V
        • Mahaffey KW
        • de Zeeuw D
        • Fulcher G
        • Erondu N
        • Shaw W
        • Law G
        • Desai M
        • Matthews DR
        CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes.
        N Engl J Med. 2017; 377: 644-657
        • Wiviott SD
        • Raz I
        • Bonaca MP
        • Mosenzon O
        • Kato ET
        • Cahn A
        • Silverman MG
        • Zelniker TA
        • Kuder JF
        • Murphy SA
        • Bhatt DL
        • Leiter LA
        • McGuire DK
        • Wilding JPH
        • Ruff CT
        • Gause-Nilsson IAM
        • Fredriksson M
        • Johansson PA
        • Langkilde AM
        • Sabatine MS
        DECLARE–TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes.
        N Engl J Med. 2019; 380: 347-357
        • Zinman B
        • Wanner C
        • Lachin JM
        • Fitchett D
        • Bluhmki E
        • Hantel S
        • Mattheus M
        • Devins T
        • Johansen OE
        • Woerle HJ
        • Broedl UC
        • Inzucchi SE
        EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.
        N Engl J Med. 2015; 373: 2117-2128
        • Brownson RC
        • Kreuter MW
        • Arrington BA
        • True WR.
        Translating scientific discoveries into public health action: how can schools of public health move us forward?.
        Public Health Rep. 2006; 121: 97-103
        • Colaco NA
        • Kazi DS.
        From molecules to markets: broadening the focus of cardiovascular innovation.
        Circ Heart Fail. 2018; 11e004815
        • Ciolino JD
        • Jackson KL
        • Liss DT
        • Brown T
        • Walunas TL
        • Murakami L
        • Chung I
        • Persell SD
        • Kho AN.
        Design of Healthy Hearts in the Heartland (H3): a practice-randomized, comparative effectiveness study.
        Contemp Clin Trials. 2018; 71: 47-54
        • Persell SD
        • Liss DT
        • Walunas TL
        • Ciolino JD
        • Ahmad FS
        • Brown T
        • French DD
        • Hountz R
        • Iversen K
        • Lindau ST
        • Lipiszko D
        • Makelarski JA
        • Mazurek K
        • Murakami L
        • Peprah Y
        • Potempa J
        • Rasmussen LV
        • Wang A
        • Wang J
        • Yeh C
        • Kho AN.
        Effects of 2 forms of practice facilitation on cardiovascular prevention in primary care: a practice-randomized, comparative effectiveness trial.
        Med Care. 2020; 58: 344-351
        • Starren JB
        • Winter AQ
        • Lloyd-Jones DM
        Enabling a learning health system through a unified enterprise data warehouse: the experience of the Northwestern University Clinical and Translational Sciences (NUCATS) Institute.
        Clin Transl Sci. 2015; 8: 269-271
        • Wiese AD
        • Roumie CL
        • Buse JB
        • Guzman H
        • Bradford R
        • Zalimeni E
        • Knoepp P
        • Morris HL
        • Donahoo WT
        • Fanous N
        • Epstein BF
        • Katalenich BL
        • Ayala SG
        • Cook MM
        • Worley KJ
        • Bachmann KN
        • Grijalva CG
        • Rothman RL
        • Chakkalakal RJ.
        Performance of a computable phenotype for identification of patients with diabetes within PCORnet: the Patient-Centered Clinical Research Network.
        Pharmacoepidemiol Drug Saf. 2019; 28: 632-639
        • Ahmad FS
        • Ricket IM
        • Hammill BG
        • Eskenazi L
        • Robertson HR
        • Curtis LH
        • Dobi CD
        • Girotra S
        • Haynes K
        • Kizer JR
        • Kripalani S
        • Roe MT
        • Roumie CL
        • Waitman R
        • Jones WS
        • Weiner MG.
        Computable phenotype implementation for a national, multicenter pragmatic clinical trial: lessons learned From ADAPTABLE.
        Circ Cardiovasc Qual Outcomes. 2020; 13e006292
        • Roumie CL
        • Patel NJ
        • Muñoz D
        • Bachmann J
        • Stahl A
        • Case R
        • Leak C
        • Rothman R
        • Kripalani S.
        Design and outcomes of the Patient Centered Outcomes Research Institute coronary heart disease cohort study.
        Contemp Clin Trials Commun. 2018; 10: 42-49
      3. Centers for Medicare and Medicaid Services. Chronic Conditions Data Warehouse. Available at: https://www2.ccwdata.org/web/guest/home. Accessed on XXX.

        • Brokamp C
        • Wolfe C
        • Lingren T
        • Harley J
        • Ryan P.
        Decentralized and reproducible geocoding and characterization of community and environmental exposures for multisite studies.
        J Am Med Inform Assoc. 2018; 25: 309-314
      4. Center for Health Disparities Research, University of Wisconsin School of Medicine and Public Health. Neighborhood atlas: area deprivation index v3.1. Available at: https://www.neighborhoodatlas.medicine.wisc.edu/. Accessed on July 7 2021.

        • Kind AJH
        • Buckingham WR.
        Making neighborhood-disadvantage metrics accessible - the Neighborhood Atlas.
        N Engl J Med. 2018; 378: 2456-2458
        • Frigaard M
        • Rubinsky A
        • Lowell L
        • Malkina A
        • Karliner L
        • Kohn M
        • Peralta CA.
        Validating laboratory defined chronic kidney disease in the electronic health record for patients in primary care.
        BMC Nephrol. 2019; 20: 3
        • American Diabetes Association
        10. Cardiovascular disease and risk management: Standards of Medical Care in Diabetes-2021.
        Diabetes Care. 2021; 44: S125-S150
        • Sidney S
        • Quesenberry Jr, CP
        • Jaffe MG
        • Sorel M
        • Nguyen-Huynh MN
        • Kushi LH
        • Go AS
        • Rana JS.
        Recent trends in cardiovascular mortality in the United States and public health goals.
        JAMA Cardiol. 2016; 1: 594-599
        • Leigh JA
        • Alvarez M
        • Rodriguez CJ.
        Ethnic minorities and coronary heart disease: an update and future directions.
        Curr Atheroscler Rep. 2016; 18: 9
        • Ruppar TM
        • Cooper PS
        • Mehr DR
        • Delgado JM
        • Dunbar-Jacob JM.
        Medication adherence interventions improve heart failure mortality and readmission rates: systematic review and meta-analysis of controlled trials.
        J Am Heart Assoc. 2016; 5e002606
        • Mason A.
        New medicines in primary care: a review of influences on general practitioner prescribing.
        J Clin Pharm Ther. 2008; 33: 1-10
        • Lublóy Á.
        Factors affecting the uptake of new medicines: a systematic literature review.
        BMC Health Serv Res. 2014; 14: 469
        • Levy AE
        • Huang C
        • Huang A
        • Ho MP.
        Recent approaches to improve medication adherence in patients with coronary heart disease: progress towards a learning healthcare system.
        Curr Atheroscler Rep. 2018; 20: 5
        • McMurray JJV
        • Packer M
        • Desai AS
        • Gong J
        • Lefkowitz MP
        • Rizkala AR
        • Rouleau JL
        • Shi VC
        • Solomon SD
        • Swedberg K
        • Zile MR
        PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure.
        N Engl J Med. 2014; 371: 993-1004
        • Greene SJ
        • Butler J
        • Albert NM
        • DeVore AD
        • Sharma PP
        • Duffy CI
        • Hill CL
        • McCague K
        • Mi X
        • Patterson JH
        • Spertus JA
        • Thomas L
        • Williams FB
        • Hernandez AF
        • Fonarow GC.
        Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry.
        J Am Coll Cardiol. 2018; 72: 351-366
      5. National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Care Services, Committee on Ensuring Patient Access to Affordable Drug Therapies. Making medicines affordable: a national imperative. Washington: National Academies Press (US); 2017.

        • Piette JD
        • Wagner TH
        • Potter MB
        • Schillinger D.
        Health insurance status, cost-related medication underuse, and outcomes among diabetes patients in three systems of care.
        Med Care. 2004; 42: 102-109
        • Piette JD
        • Heisler M
        • Wagner TH.
        Cost-related medication underuse among chronically ill adults: the treatments people forgo, how often, and who is at risk.
        Am J Public Health. 2004; 94: 1782-1787
        • Persaud N
        • Bedard M
        • Boozary AS
        • Glazier RH
        • Gomes T
        • Hwang SW
        • Juni P
        • Law MR
        • Mamdani MM
        • Manns BJ
        • Martin D
        • Morgan SG
        • Oh PI
        • Pinto AD
        • Shah BR
        • Sullivan F
        • Umali N
        • Thorpe KE
        • Tu K
        • Laupacis A
        Carefully Selected and Easily Accessible at No Charge Medicines (CLEAN Meds) Study Team. Effect on treatment adherence of distributing essential medicines at no charge: the CLEAN Meds randomized clinical trial.
        JAMA Intern Med. 2019; 180: 27-34
        • Madden JM
        • Graves AJ
        • Zhang F
        • Adams AS
        • Briesacher BA
        • Ross-Degnan D
        • Gurwitz JH
        • Pierre-Jacques M
        • Safran DG
        • Adler GS
        • Soumerai SB
        Cost-related medication nonadherence and spending on basic needs following implementation of Medicare Part D.
        JAMA. 2008; 299: 1922-1928
        • Sokol MC
        • McGuigan KA
        • Verbrugge RR
        • Epstein RS.
        Impact of medication adherence on hospitalization risk and healthcare cost.
        Med Care. 2005; 43: 521-530
        • Ho PM
        • Rumsfeld JS
        • Masoudi FA
        • McClure DL
        • Plomondon ME
        • Steiner JF
        • Magid DJ.
        Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus.
        Arch Intern Med. 2006; 166: 1836-1841
        • Youmans QR
        • Hastings-Spaine L
        • Princewill O
        • Shobayo T
        • Okwuosa IS.
        Disparities in cardiovascular care: past, present, and solutions.
        Cleve Clin J Med. 2019; 86: 621-632
        • Peek ME
        • Cargill A
        • Huang ES.
        Diabetes health disparities: a systematic review of health care interventions.
        Med Care Res Rev. 2007; 64: 101S-156S
        • Johnson PA
        • Lee TH
        • Cook EF
        • Rouan GW
        • Goldman L.
        Effect of race on the presentation and management of patients with acute chest pain.
        Ann Intern Med. 1993; 118: 593-601
        • Eberly LA
        • Yang L
        • Eneanya ND
        • Essien U
        • Julien H
        • Nathan AS
        • Khatana SAM
        • Dayoub EJ
        • Fanaroff AC
        • Giri J
        • Groeneveld PW
        • Adusumalli S.
        Association of race/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US.
        JAMA Netw Open. 2021; 4e216139
        • Yancy CW.
        COVID-19 and African Americans.
        JAMA. 2020; 323: 1891-1892
        • Purnell TS
        • Calhoun EA
        • Golden SH
        • Halladay JR
        • Krok-Schoen JL
        • Appelhans BM
        • Cooper LA.
        Achieving health equity: closing the gaps in health care disparities, interventions, and research.
        Health Aff (Millwood). 2016; 35: 1410-1415
      6. Institute of Medicine (US) Committee on Understanding and Eliminating Racial and Ethnic Disparities in Health Care. Unequal treatment: confronting racial and ethnic disparities in health care. Washington: National Academies Press (US); 2003.